As the average age of the U.S. population and the number of patients at high risk for cardiovascular disease increase, the usage of cardio and endovascular stents continues to grow. Interventional cardiologists and registered nurses in the U.S. were recently asked about their perceptions and attitudes regarding current percutaneous coronary interventional (PCI) procedures and devices. They were also asked their stent brand and drug type preferences. In a statistically significant survey, they divulged which procedures and manufactures they preferred. This window into micro level stent usage offers informed insights into the overall market and reveals how dynamics between medical organizations and device manufacturers contribute to market trends.

July 16, 2012 — TriReme Medical Inc. (TMI) announced today that it has received U.S. Food and Drug Administration (FDA) clearance for an expanded matrix of sizes for its unique Glider PTCA balloon catheter.

Mercator MedSystems, a medical technology company whose platform Micro-Infusion Catheter technology announced preliminary results of its DANCE clinical trial that continues to follow patients at the University of California, San Francisco (UCSF) and  San Francisco VA Medical Center. The technology offers catheter-guided, microfluid injection systems for site-specific, nonsystemic delivery of therapeutic agents directly across any peripheral or coronary blood vessel to treat peripheral vascular diseases, cancer, heart attacks, and other life-threatening diseases and disorders.


July 16, 2012 — The American College of Cardiology (ACC) and the American College of Radiology (ACR) are warning that the extreme cuts to funding for medical imaging scans in the 2013 Medicare Physician Fee Schedule Proposed Rule are unnecessary, unfounded and will undermine patient care.

July 16, 2012 — Reva Medical Inc. announced it completed clinical enrollment with the ReZolve drug-eluting bioresorbable scaffold. A total of 26 patients have been enrolled and there are no major adverse coronary events (MACE) reported to date.

 

July 16, 2012 — LipoScience Inc., an in vitro diagnostic company developing clinical diagnostic tests using nuclear magnetic resonance (NMR) technology, announced publication of the findings of a clinical study in the current issue of the Journal of the American College of Cardiology indicating that high density lipoprotein (HDL) particle number has a stronger, more independent association with coronary heart disease and carotid atherosclerosis than HDL cholesterol (HDL-C).

 

July 16, 2012 — Medical imaging has always been an important part of clinical trials.  Echocardiography, which uses sound waves to create moving real-time images of cardiac structure and function, provides an excellent noninvasive method to evaluate the impact of therapeutics on cardiac morphology.

July 16, 2012 — The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $4.78 million grant to researchers at Cleveland Clinic’s Lerner Research Institute to use metabolomics — a new approach that focuses on the small-molecule byproducts of metabolism —  for discovery of novel pathways linked to the development of cardiovascular diseases.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now